Company Overview and News
Mumbai: Rising for the fifth straight session, market benchmark Sensex gained 60 points to end at 33,940 in see-saw trade today, led by gains in metal, IT and consumer durables counters amid mixed Asian cues.
The NSE on Monday moved 15 stocks to the trade-for-trade segment from Thursday at a price band of 5 per cent. The stocks are Aditya Birla Money, Burnpur Cement, Cantabil Retail India, Dharani Sugars & Chemicals, D-Link (India), DQ Entertainment (International), MIC Electronics, Petron Engineering Construction, Super Spinning Mills, Shilpi Cables, Tanla Solutions and Tera Software. Under the trade-for-trade segment, delivery of shares and payment of consideration amount are compulsory.
In a major relief ahead of Essar Steel bidding, ArcelorMittal has received approval from the exchanges to change its promoter status in Uttam Galva Steels. Sources told Moneycontrol the exchanges have declassified ArcelorMittal as promoter of Uttam Galva.
Our Bureau PNB loan scam co-accused Mehul Choksi’s Gitanjali Gems has been fined by the NSE for failure to file financial results for the quarter ended December, 2017. The company may be suspended from trading if it does not file its results, which it is likely to do.
Our Bureau The consent applications of 12 NSE officials show-caused by SEBI in the algo-related case of unfair access have been returned by the regulator pending investigations. SEBI has said the applications can be filed only after investigations are complete.
(Reuters) - The Sensex edged down on Thursday, as subdued global market sentiment offset better-than-expected growth data at home, with bank stocks such as ICICI Bank and State Bank of India among the big losers.
Pratim Ranjan Bose Till about two weeks ago, not many in Bangladesh cared for Dhaka Stock Exchange (DSE) and its demutualisation drive, approved in 2013, to separate the ownership from the management run by member brokers.
Mumbai: The benchmark BSE Sensex gained 173 points to 34,473.43 in early trade today, rising for the second straight session on back of positive macroeconomic data and sustained buying by domestic institutional investors (DIIs) amid appreciating rupee.
Pierre-Henri Flamand, the Chief Investment Officer of Man Group’s GLG unit, said market swings could continue and warned against a tendency to “buy-the-dip” after a correction in global markets. “The instinctive inclination to ‘buy-the-dip’ may be strong,” Flamand told Bloomberg. “As the past week has shown, this may not work so well. Indeed, what we have seen in the past week could continue for some time.
The United States may be looking more favourably at diplomatic engagement with North Korea, possibly holding dialogue, as South Korea pushes forward with plans to establish grounds for a rare summit between the two Koreas, reports Reuters. Vice President Mike Pence said the United States and South Korea had agreed on terms for further diplomatic engagement with North Korea, first with Seoul and then possibly leading to direct talks with Washington without pre-conditions.
The bad loan situation appears to be improving for private as well as public sector banks (PSBs) as the pipeline of accounts that may turn into stressed assets is shrinking. According to the Kotak Institutional Equities report, the overall trends on Special Mention Accounts (SMAs) portfolio is on a decline.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...